Skip to main content
Premium Trial:

Request an Annual Quote

PGDx, MolecularMD Ink Co-Marketing Deal

NEW YORK (GenomeWeb News) – Personal Genome Diagnostics today announced a deal with MolecularMD to market personalized medicine services to oncology researchers and drug developers.

The deal combines PGDx's expertise in next-generation sequencing-based cancer biomarker discovery with MolecularMD's capabilities in developing and validating cancer companion diagnostics, PGDx said. Under the agreement's terms, the two companies will co-market each other's services to drug manufacturers and biotechnology customers.

Further financial terms were not disclosed.

Baltimore-based PGDx provides genome mapping services and analyses to cancer researchers, clinicians, and patients. In the spring it announced a collaboration with BluePrint Medicines aimed at novel kinase targets for cancer drugs. The company licenses digital karyotyping technology from Johns Hopkins University that was developed by PGDx's founders.

MolecularMD, headquartered in Portland, Ore., provides molecular diagnostic products and services to the pharmaceutical and biotechnology sector.

"This collaboration will now enable the two companies to provide a complete spectrum of genomic services to drug developers," Antony Newton, chief commercial officer of PGDx, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.